Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)

Inclusion Criteria: * Healthy. * Subject/Parents/legal guardian(s) have been informed properly regarding the study and signed the informed consent form/and informed assent form. * Subject/parents/legal guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial. Exclusion Criteria: * Subject concomitantly enrolled or scheduled to be enrolled in another trial. * Evolving mild, moderate or severe illness, especially infectious diseases or fever (axilary temperature ³ 37.5°C). * Known history of allergy to any component of the vaccines. * History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection. * Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, corticosteroid therapy and other immunosuppressants) * Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives. * Pregnancy \& lactation (Adults). * Individuals who have previously received any vaccines against typhoid fever. * Subjects already vaccinated with any vaccine within one month prior and expect to receive other vaccines within one month following vaccination except MR (Measles Rubella) vaccine. * Individuals who have a previously ascertained typhoid fever by laboratory confirmation (blood culture/new rapid test) at any time. * Subject planning to move from the study area before the end of study period.